Modulation of autophagy by sorafenib: Effects on treatment response

Frontiers in Pharmacology

Volumn 7, Issue JUN, 2016, Pages

  Prieto Domínguez, Nestor ^a,b   Ordóñez, Raquel ^a,b   Fernández, Anna ^a,b   García Palomo, Andres ^c   Muntané, Jordi ^a,d   González Gallego, Javier ^a,b   Mauriz, José L ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF LEÓN   (Spain)

^c Departamento de Cardiología   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Autophagy; Cancer therapeutic; Dug resistance; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ADENYLATE KINASE; BECLIN 1; DOXORUBICIN; HERBACEOUS AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; MICRORNA 30ALPHA; PROTEIN BCL 2; PROTEIN MCL 1; SILDENAFIL; SORAFENIB; SPHINGOLIPID; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AUTOPHAGY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MODULATION; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA ANALYSIS; SURVIVAL RATE;

EID: 84977608039     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00151     Document Type: Review

References (144)

1. Abdel-Rahman, O., and Fouad, M. (2014). Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit. Rev. Oncol. Hematol. 91, 1-8. doi: 10.1016/j.critrevonc.2013.12.013
2. Adnane, L., Trail, P. A., Taylor, I., and Wilhelm, S. M. (2006). Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407, 597-612. doi: 10.1016/S0076-6879(05)07047-3
3. Alonso-Gordoa, T., Diez, J. J., Duran, M., Grande, E., Díez, J. J., Durán, M., et al. (2015). Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 22-38. doi: 10.1177/1758834014551936
4. Antar, A., Kharfan-Dabaja, M. A., Mahfouz, R., and Bazarbachi, A. (2014). Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin. Lymphoma. Myeloma Leuk. 15, 298-302. doi: 10.1016/j.clml.2014.12.005
5. Bareford, M. D., Hamed, H. A., Tang, Y., Cruickshanks, N., Burow, M. E., Fisher, P. B., et al. (2011a). Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy 7, 1261-1262. doi: 10.4161/auto.7.10.17029
6. Bareford, M. D., Park, M. A., Yacoub, A., Hamed, H. A., Tang, Y., Cruickshanks, N., et al. (2011b). Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res. 71, 4955-4967. doi: 10.1158/0008-5472.CAN-11-0898
7. Beljanski, V., Lewis, C. S., and Smith, C. D. (2011). Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol. Ther. 11, 524-534. doi: 10.4161/cbt.11.5.14677
8. Booth, L., Roberts, J. L., Cruickshanks, N., Conley, A., Durrant, D. E., Das, A., et al. (2014). Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol. Pharmacol. 85, 408-419. doi: 10.1124/mol.113.090043
9. Campello, S., Strappazzon, F., and Cecconi, F. (2014). Mitochondrial dismissal in mammals, from protein degradation to mitophagy. Biochim. Biophys. Acta Bioenerg. 1837, 451-460. doi: 10.1016/j.bbabio.2013.11.010
10. Carr, B. I., Cavallini, A., Lippolis, C., D'Alessandro, R., Messa, C., Refolo, M. G., et al. (2013). Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J. Cell. Physiol. 228, 292-297. doi: 10.1002/jcp.24148
11. Cervello, M., Bachvarov, D., Lampiasi, N., Cusimano, A., Azzolina, A., McCubrey, J. A., et al. (2012). Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 11, 2843-2855. doi: 10.4161/cc.21193
12. Chen, K. F., Tai, W. T., Liu, T. H., Huang, H. P., Lin, Y. C., Shiau, C. W., et al. (2010). Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 16, 5189-5199. doi: 10.1158/1078-0432.CCR-09-3389
13. Chi, K. N., Ellard, S. L., Hotte, S. J., Czaykowski, P., Moore, M., Ruether, J. D., et al. (2008). A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol. 19, 746-751. doi: 10.1093/annonc/mdm554
14. Chiou, J. F., Tai, C. J., Huang, M. T., Wei, P. L., Wang, Y. H., An, J., et al. (2010). Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann. Surg. Oncol. 17, 603-612. doi: 10.1245/s10434-009-0718-8
15. Choi, K. S. (2012). Autophagy and cancer. Exp. Mol. Med. 44, 109-120. doi: 10.3858/emm.2012.44.2.033
16. Crespo, I., San-Miguel, B., Prause, C., Marroni, N., Cuevas, M. J., González-Gallego, J., et al. (2012). Glutamine Treatment Attenuates Endoplasmic Reticulum Stress and Apoptosis in TNBS-Induced Colitis. PLoS ONE 7:E50407. doi: 10.1371/journal.pone.0050407
17. Das, A., Durrant, D., Salloum, F. N., Xi, L., and Kukreja, R. C. (2015). PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol. Ther. 147, 12-21. doi: 10.1016/j.pharmthera.2014.10.003
18. Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., et al. (2014). Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3:e02523. doi: 10.7554/eLife.02523
19. Dokmanovic, M., Clarke, C., and Marks, P. A. (2007). Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981-989. doi: 10.1158/1541-7786.MCR-07-0324
20. Donadon, V., Balbi, M., Mas, M. D., Casarin, P., and Zanette, G. (2010). Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 30, 750-758. doi: 10.1111/j.1478-3231.2010.02223.x
21. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschi, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in differentiated mouse ES cells. Nature 411, 494-498. doi: 10.1038/35078107
22. Erber, R., Thurnher, A., Katsen, A. D., Groth, G., Kerger, H., Hammes, H. P., et al. (2004). Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18, 338-340. doi: 10.1096/fj.03-0271fje
23. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134. doi: 10.4161/cbt.10.12.13497
24. Eskelinen, E. L. (2011). The dual role of autophagy in cancer. Curr. Opin. Pharmacol. 11, 294-300. doi: 10.1016/j.coph.2011.03.009
25. Eulitt, P. J., Park, M. A., Hossein, H., Cruikshanks, N., Yang, C., Dmitriev, I. P., et al. (2010). Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol. Ther. 10, 1290-1305. doi: 10.4161/cbt.10.12.13497
26. Eum, K. H., Ahn, S. K., Kang, H., and Lee, M. (2013). Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Mol. Cell. Biochem. 372, 65-74. doi: 10.1007/s11010-012-1446-0
27. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386. doi: 10.1002/ijc.29210
28. Fernández, A., Ordóñez, R., Reiter, R. J., González-Gallego, J., and Mauriz, J. L. (2015). Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. J. Pineal Res. 59, 292-307. doi: 10.1111/jpi.12264
29. Fischer, T. D., Wang, J. H., Vlada, A., Kim, J. S., and Behrns, K. E. (2014). Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World J. Hepatol. 6, 752-758. doi: 10.4254/wjh.v6.i10.752
30. Forner, A., Llovet, J. M., and Bruix, J. (2012). Hepatocellular carcinoma. Lancet 379, 1245-1255. doi: 10.1016/S0140-6736(11)61347-0
31. Fumarola, C., Caffarra, C., La Monica, S., Galetti, M., Alfieri, R. R., Cavazzoni, A., et al. (2013). Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res. Treat. 141, 67-78. doi: 10.1007/s10549-013-2668-x
32. Gauthier, A., and Ho, M. (2013). Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol. Res. 43, 147-154. doi: 10.1111/j.1872-034X.2012.01113.x
33. Gedaly, R., Angulo, P., Hundley, J., Daily, M. F., Chen, C., Koch, A., et al. (2010). PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 30, 4951-4958.
34. Germain, M., Nguyen, A. P., Le Grand, J. N., Arbour, N., Vanderluit, J. L., Park, D. S., et al. (2011). MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J. 30, 395-407. doi: 10.1038/emboj.2010.327
35. Giannini, G., Cabri, W., Fattorusso, C., and Rodriquez, M. (2012). Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med. Chem. 4, 1439-1460. doi: 10.4155/fmc.12.80
36. Gollob, J. A., Rathmell, W. K., Richmond, T. M., Marino, C. B., Miller, E. K., Grigson, G., et al. (2007). Phase II trial of sorafenib plus interferon alfa-2β as first-or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 25, 3288-3295. doi: 10.1200/JCO.2007.10.8613
37. Gonzalez, S. A. (2014). Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg. Nutr. 3, 410-414. doi: 10.3978/j.issn.2304-3881.2014.07.06
38. Grahame Hardie, D. (2014). AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J. Intern. Med. 276, 543-559. doi: 10.1111/joim.12268
39. Groenendijk, F. H., Mellema, W. W., van der Burg, E., Schut, E., Hauptmann, M., Horlings, H. M., et al. (2015). Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int. J. Cancer 136, 1434-1444. doi: 10.1002/ijc.29113
40. Guan, Y. S., and He, Q. (2011). Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert. Opin. Pharmacother. 12, 303-313. doi: 10.1517/14656566.2011.546346
41. Guidetti, A., Carlo-Stella, C., Locatelli, S. L., Malorni, W., Pierdominici, M., Barbati, C., et al. (2012). Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br. J. Haematol. 158, 108-119. doi: 10.1111/j.1365-2141.2012.09139.x
42. Gulhati, P., Zaytseva, Y. Y., Valentino, J. D., Stevens, P. D., Kim, J. T., Sasazuki, T., et al. (2012). Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis 33, 1782-1790. doi: 10.1093/carcin/bgs203
43. Hamed, H. A., Tavallai, S., Grant, S., Poklepovic, A., and Dent, P. (2015). Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. J. Cell. Physiol. 230, 131-139. doi: 10.1002/jcp.24689
44. Hannun, Y. A., and Obeid, L. M. (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Cell Biol. 9, 139-150. doi: 10.1038/nrm2329
45. Harvald, E. B., Olsen, A. S., and Faergeman, N. J. (2015). Autophagy in the light of sphingolipid metabolism. Apoptosis 20, 658-670. doi: 10.1007/s10495-015-1108-2
46. He, C., and Klionsky, D. J. (2009). Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43, 67-93. doi: 10.1146/annurev-genet-102808-114910
47. Holz, M. S., Janning, A., Renné, C., Gattenlöhner, S., Spieker, T., and Bräuninger, A. (2013). Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines. Mol. Cancer Ther. 12, 173-183. doi: 10.1158/1535-7163.mct-12-0532
48. Honma, Y., and Harada, M. (2013). Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation. Exp. Cell Res. 319, 2166-2178. doi: 10.1016/j.yexcr.2013.05.023
49. Jakubowicz-Gil, J., Langner, E., Badziul, D., Wertel, I., and Rzeski, W. (2014). Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. Neurotox. Res. 26, 64-77. doi: 10.1007/s12640-013-9452-x
50. Jheng, J. R., Ho, J. Y., and Horng, J. T. (2014). ER stress, autophagy, and RNA viruses. Front. Microbiol. 5:388. doi: 10.3389/fmicb.2014.00388
51. Jiang, X., Kanda, T., Nakamoto, S., Miyamura, T., Wu, S., and Yokosuka, O. (2014). Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. Exp. Cell Res. 323, 326-336. doi: 10.1016/j.yexcr.2014.02.017
52. Kania, E., Pajak, B., and Orzechowski, A. (2015). Calcium homeostasis and ER stress in control of autophagy in cancer cells. Biomed Res. Int. 2015:352794. doi: 10.1155/2015/352794
53. Kharaziha, P., Ceder, S., Sanchez, C., and Panaretakis, T. (2013). Multitargeted therapies for multiple myeloma. Autophagy 9, 255-257. doi: 10.4161/auto.22738
54. Kharaziha, P., De Raeve, H., Fristedt, C., Li, Q., Gruber, A., Johnsson, P., et al. (2012). Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res. 72, 5348-5362. doi: 10.1158/0008-5472.CAN-12-0658
55. Knievel, J., Schulz, W. A., Greife, A., Hader, C., Lubke, T., Schmitz, I., et al. (2014). Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. Int. J. Mol. Sci. 15, 20500-20517. doi: 10.3390/ijms151120500
56. Kowalik, M. A., Perra, A., Ledda-Columbano, G. M., Ippolito, G., Piacentini, M., Columbano, A., et al. (2016). Induction of autophagy promotes the growth of early preneoplastic rat liver nodules. Oncotarget 7, 5788-5799. doi: 10.18632/oncotarget.6810
57. Kummar, S., Copur, M. S., Rose, M., Wadler, S., Stephenson, J., O'Rourke, M., et al. (2011). A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 10, 85-96. doi: 10.1016/j.clcc.2011.03.003
58. Lam, W., Jiang, Z., Guan, F., Huang, X., Hu, R., Wang, J., et al. (2015). PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci. Rep. 5:9384. doi: 10.1038/srep09384
59. Lan, S.-H., Wu, S.-Y., Zuchini, R., Lin, X.-Z., Su, I.-J., Tsai, T.-F., et al. (2014). Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 59, 505-517. doi: 10.1002/hep.26659
60. Li, Y., Li, S., Qin, X., Hou, W., Dong, H., Yao, L., et al. (2014). The pleiotropic roles of sphingolipid signaling in autophagy. Cell Death Dis. 5, e1245. doi: 10.1038/cddis.2014.215
61. Lian, J., Ni, Z., Dai, X., Su, C., Smith, A. R., Xu, L., et al. (2012). Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Mol. Cancer Ther. 11, 416-426. doi: 10.1158/1535-7163.MCT-11-0559
62. Lin, C. I., Whang, E. E., Lorch, J. H., and Ruan, D. T. (2012). Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery 152, 1142-1149. doi: 10.1016/j.surg.2012.08.016
63. Lin, J.-C., Liu, C.-L., Lee, J.-J., Liu, T.-P., Ko, W.-C., Hung, Y. C., et al. (2013). Sorafenib induces autophagy and suppresses activation of human macrophage. Int. Immunopharmacol. 15, 333-339. doi: 10.1016/j.intimp.2013.01.006
64. Lindqvist, L. M., Heinlein, M., Huang, D. C., and Vaux, D. L. (2014). Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. Proc. Natl. Acad. Sci. U.S.A. 111, 8512-8517. doi: 10.1073/pnas.1406425111
65. Liu, J., Fan, L., Wang, H., and Sun, G. (2016). Autophagy, a double-edged sword in anti-angiogenesis therapy. Med. Oncol. 33, 1-13. doi: 10.1007/s12032-015-0721-9
66. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66, 11851-11858. doi: 10.1158/0008-5472.CAN-06-1377
67. Liu, L., Ho, R. L. K., Chen, G. G., and Lai, P. B. S. (2012). Sorafenib inhibits hypoxia-inducible factor-1a synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin. Cancer Res. 18, 5662-5671. doi: 10.1158/1078-0432.CCR-12-0552
68. Liu, S. H., and Cheng, Y. C. (2012). Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J. Ethnopharmacol. 140, 614-623. doi: 10.1016/j.jep.2012.01.047
69. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390. doi: 10.1056/NEJMoa0708857
70. Luo, Y., Shi, Y., Xing, P., Wang, L., Feng, Y., Han, X., et al. (2014). Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: a pilot study. Mol. Clin. Oncol. 2, 87-92. doi: 10.3892/mco.2013.199
71. Malhi, H., and Kaufman, R. J. (2011). Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795-809. doi: 10.1016/j.jhep.2010.11.005
72. Manov, I., Pollak, Y., Broneshter, R., and Iancu, T. C. (2011). Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib-the role of extracellular signal-regulated kinase counteraction. FEBS J. 278, 3494-3507. doi: 10.1111/j.1742-4658.2011.08271.x
73. Manwani, B., and McCullough, L. D. (2013). Function of the master energy regulator adenosine monophosphate-activated protein kinase in stroke. J. Neurosci. Res. 91, 1018-1029. doi: 10.1002/jnr.23207
74. Martin, A. P., Park, M. A., Mitchell, C., Walker, T., Rahmani, M., Thorburn, A., et al. (2009). BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol. Pharmacol. 76, 327-341. doi: 10.1124/mol.109.056309
75. Mizushima, N., and Komatsu, M. (2011). Autophagy: renovation of cells and tissues. Cell 147, 728-741. doi: 10.1016/j.cell.2011.10.026
76. Mizushima, N. (2010). The role of the Atg1/ULK1 complex in autophagy regulation. Curr. Opin. Cell Biol. 22, 132-139. doi: 10.1016/j.ceb.2009.12.004
77. Morales, A., Mari, M., Garcia-Ruiz, C., Colell, A., and Fernandez-Checa, J. C. (2012). Hepatocarcinogenesis and ceramide/cholesterol metabolism. Anticancer Agents Med. Chem. 12, 364-375. doi: 10.2174/187152012800228689
78. Motoshima, H., Goldstein, B. J., Igata, M., and Araki, E. (2006). AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 574, 63-71. doi: 10.1113/jphysiol.2006.108324
79. Mukhopadhyay, S., Panda, P. K., Sinha, N., Das, D. N., and Bhutia, S. K. (2014). Autophagy and apoptosis: where do they meet? Apoptosis 19, 555-566. doi: 10.1007/s10495-014-0967-2
80. Neufeld, T. P. (2010). TOR-dependent control of autophagy: biting the hand that feeds. Curr. Opin. Cell Biol. 22, 157-168. doi: 10.1016/j.ceb.2009.11.005
81. Niessner, H., Beck, D., Sinnberg, T., Lasithiotakis, K., Maczey, E., Gogel, J., et al. (2011). The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J. Invest. Dermatol. 131, 468-479. doi: 10.1038/jid.2010.297
82. Novikova, D. S., Garabadzhiu, A. V., Melino, G., Barlev, N. A., and Tribulovich, V. G. (2015). AMP-activated protein kinase: structure, function, and role in pathological processes. Biochemistry 80, 127-144. doi: 10.1134/S0006297915020017
83. Ordoñez, R., Fernández, A., Prieto-Domínguez, N., Martínez, L., García-Ruiz, C., Fernández-Checa, J. C., et al. (2015). Ceramide metabolism regulates autophagy and apoptotic-cell death induced by melatonin in liver cancer cells. J. Pineal Res. 59, 178-189. doi: 10.1111/jpi.12249
84. Orsi, A., Polson, H. E., and Tooze, S. A. (2010). Membrane trafficking events that partake in autophagy. Curr. Opin. Cell Biol. 22, 150-156. doi: 10.1016/j.ceb.2009.11.013
85. Park, M. A., Reinehr, R., Haussinger, D., Voelkel-Johnson, C., Ogretmen, B., Yacoub, A., et al. (2010). Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol. Cancer Ther. 9, 2220-2231. doi: 10.1158/1535-7163.MCT-10-0274
86. Park, M. A., Zhang, G., Martin, A. P., Hamed, H., Mitchell, C., Hylemon, P. B., et al. (2008). Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol. Ther. 7, 1648-1662. doi: 10.4161/cbt.7.10.6623
87. 2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy. Mol. Pharmacol. 80, 1066-1075. doi: 10.1124/mol.111.071761
88. Pignochino, Y., Dell'Aglio, C., Basirico, M., Capozzi, F., Soster, M., Marchio, S., et al. (2013). The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin. Cancer Res. 19, 2117-2131. doi: 10.1158/1078-0432.CCR-12-2293
89. Pignochino, Y., Dell'Aglio, C., Inghilleri, S., Zorzetto, M., Basirico, M., Capozzi, F., et al. (2015). The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer 15:374. doi: 10.1186/s12885-015-1363-1
90. Rahmani, M., Davis, E. M., Bauer, C., Dent, P., and Grant, S. (2005). Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227. doi: 10.1074/jbc. M506551200
91. Rahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent, P., et al. (2007). The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol. 27, 5499-5513. doi: 10.1128/MCB.01080-06
92. Ramakrishnan, V., Timm, M., Haug, J. L., Kimlinger, T. K., Halling, T., Wellik, L. E., et al. (2012). Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am. J. Hematol. 87, 277-283. doi: 10.1002/ajh.22263
93. Rehman, G., Shehzad, A., Khan, A. L., and Hamayun, M. (2014). Role of AMP-activated protein kinase in cancer therapy. Arch. Pharm. (Weinheim). 347, 457-468. doi: 10.1002/ardp.201300402
94. Rockwell, S., Grove, T. A., Liu, Y., Cheng, Y. C., Higgins, S. A., and Booth, C. J. (2013). Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. Int. J. Radiat. Biol. 89, 16-25. doi: 10.3109/09553002.2012.717733
95. Romaine, S. P., Tomaszewski, M., Condorelli, G., and Samani, N. J. (2015). MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart 101, 921-928. doi: 10.1136/heartjnl-2013-305402
96. Rossi, L., Zoratto, F., Papa, A., Iodice, F., Minozzi, M., Frati, L., et al. (2010). Current approach in the treatment of hepatocellular carcinoma. World J. Gastrointest. Oncol. 2, 348-359. doi: 10.4251/wjgo.v2.i9.348
97. Sakai, K., Takeda, H., Nishijima, N., Orito, E., Joko, K., Uchida, Y., et al. (2015). Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget 6, 21636-21644. doi: 10.18632/oncotarget.4270
98. San-Miguel, B., Crespo, I., Sánchez, D. I., González-Fernández, B., Ortiz de Urbina, J. J., Tuñón, M. J., et al. (2015). Melatonin inhibits autophagy and endoplasmic reticulum stress in mice with carbon tetrachloride-induced fibrosis. J. Pineal Res. 59, 151-162. doi: 10.1111/jpi.12247
99. San-Miguel, B., Crespo, I., Vallejo, D., Alvarez, M., Prieto, J., González-Gallego, J., et al. (2014). Melatonin modulates the autophagic response in acute liver failure induced by the rabbit hemorrhagic disease virus. J. Pineal Res. 56, 313-321. doi: 10.1111/jpi.12124
100. Sarkar, S. (2013). Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem. Soc. Trans. 41, 1103-1130. doi: 10.1042/BST20130134
101. Scarlatti, F., Bauvy, C., Ventruti, A., Sala, G., Cluzeaud, F., Vandewalle, A., et al. (2004). Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279, 18384-18391. doi: 10.1074/jbc. M313561200
102. Sengupta, S., Peterson, T. R., and Sabatini, D. M. (2010). Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 40, 310-322. doi: 10.1016/j.molcel.2010.09.026
103. Serova, M., de Gramont, A., Tijeras-Raballand, A., Dos Santos, C., Riveiro, M. E., Slimane, K., et al. (2013). Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother. Pharmacol. 71, 1297-1307. doi: 10.1007/s00280-013-2129-6
104. Shi, Y.-H. H., Ding, Z.-B. B., Zhou, J., Hui, B., Shi, G.-M. M., Ke, A.-W. W., et al. (2011). Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 7, 1159-1172. doi: 10.4161/auto.7.10.16818
105. Shimizu, S., Takehara, T., Hikita, H., Kodama, T., Tsunematsu, H., Miyagi, T., et al. (2012). Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int. J. Cancer. J. 131, 548-557. doi: 10.1002/ijc.26374
106. Sou, Y. S., Waguri, S., Iwata, J., Ueno, T., Fujimura, T., Hara, T., et al. (2008). The Atg8 conjugation system is indispensable for proper development of autophagic isolation membranes in mice. Mol. Biol. Cell 19, 4762-4775. doi: 10.1091/mbc. E08-03-0309
107. Stiuso, P., Potenza, N., Lombardi, A., Ferrandino, I., Monaco, A., Zappavigna, S., et al. (2015). MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol. Ther. Acids 4, e233. doi: 10.1038/mtna.2015.8
108. Sui, X., Zhu, J., Zhou, J., Wang, X., Li, D., Han, W., et al. (2015). Epigenetic modifications as regulatory elements of autophagy in cancer. Cancer Lett. 360, 106-113. doi: 10.1016/j.canlet.2015.02.009
109. Sun, K., Guo, X.-L., Zhao, Q., Jing, Y., Kou, X., Xie, X., et al. (2013). Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats. Cell Death Dis. 4, e501. doi: 10.1038/cddis.2013.35
110. Sviripa, V., Zhang, W., Conroy, M. D., Schmidt, E. S., Liu, A. X., Truong, J., et al. (2013). Fluorinated, N, N'-diarylureas as AMPK activators. Bioorg. Med. Chem. Lett. 23, 1600-1603. doi: 10.1016/j.bmcl.2013.01.096
111. Tai, W. T., Shiau, C. W., Chen, H. L., Liu, C. Y., Lin, C. S., Cheng, A. L., et al. (2013). Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 4, e485. doi: 10.1038/cddis.2013.18
112. Tang, Y., Yacoub, A., Hamed, H. A., Poklepovic, A., Tye, G., Grant, S., et al. (2012). Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biol. Ther. 13, 567-574. doi: 10.4161/cbt.19771
113. Tanida, I. (2011). Autophagy basics. Microbiol. Immunol. 55, 1-11. doi: 10.1111/j.1348-0421.2010.00271.x
114. Tavallai, M., Hamed, H. A., Roberts, J. L., Cruickshanks, N., Chuckalovcak, J., Poklepovic, A., et al. (2015). Nexavar/stivarga and viagra interact to kill tumor cells. J. Cell. Physiol. 230, 2281-2298. doi: 10.1002/jcp.24961
115. Tesori, V., Piscaglia, A. C., Samengo, D., Barba, M., Bernardini, C., Scatena, R., et al. (2015). The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci. Rep. 5:9149. doi: 10.1038/srep09149
116. Tian, Y., Kuo, C., Sir, D., Wang, L., Govindarajan, S., Petrovic, L. M., et al. (2015). Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. Cell Death Differ. 22, 1025-1034. doi: 10.1038/cdd.2014.201
117. Togashi, Y., and Nishio, K. (2015). Kinase inhibitors and their resistance. Nihon Rinsho. 73, 1323-1329.
118. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108. doi: 10.3322/caac.21262
119. Tsujimoto, Y., and Shimizu, S. (2005). Another way to die: autophagic programmed cell death. Cell Death Differ. 12(Suppl. 2), 1528-1534. doi: 10.1038/sj.cdd.4401777
120. Tuñón, M. J., San-Miguel, B., Crespo, I., Laliena, A., Vallejo, D., Álvarez, M., et al. (2013). Melatonin treatment reduces endoplasmic reticulum stress and modulates the unfolded protein response in rabbits with lethal fulminant hepatitis of viral origin. J. Pineal Res. 55, 221-228. doi: 10.1111/jpi.12063
121. Ulivi, P., Arienti, C., Amadori, D., Fabbri, F., Carloni, S., Tesei, A., et al. (2009). Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J. Cell. Physiol. 220, 214-221. doi: 10.1002/jcp.21753
122. Ullen, A., Farnebo, M., Thyrell, L., Mahmoudi, S., Kharaziha, P., Lennartsson, L., et al. (2010). Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int. J. Oncol. 37, 15-20. doi: 10.3892/ijo_00000648
123. Vallejo, D., Crespo, I., San-Miguel, B., Alvarez, M., Prieto, J., Tuñón, M. J., et al. (2014). Autophagic response in the Rabbit Hemorrhagic Disease, an animal model of virally-induced fulminant hepatic failure. Vet. Res. 45:15. doi: 10.1186/1297-9716-45-15
124. van der Veen, A. G., and Ploegh, H. L. (2012). Ubiquitin-like proteins. Annu. Rev. Biochem. 81, 323-357. doi: 10.1146/annurev-biochem-093010-153308
125. Verfaillie, T., Salazar, M., Velasco, G., and Agostinis, P. (2010). Linking ER stress to autophagy: potential implications for cancer therapy. Int. J. Cell Biol. 2010:930509. doi: 10.1155/2010/930509
126. Walker, T., Mitchell, C., Park, M. A., Yacoub, A., Graf, M., Rahmani, M., et al. (2009). Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and-independent mechanisms. Mol. Pharmacol. 76, 342-355. doi: 10.1124/mol.109.056523
127. Wecksler, A. T., Hwang, S. H., Wettersten, H. I., Gilda, J. E., Patton, A., Leon, L. J., et al. (2014). Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer. Drugs 25, 433-446. doi: 10.1097/CAD.0000000000000079
128. Wellbrock, C., Karasarides, M., and Marais, R. (2004). The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885. doi: 10.1038/nrm1498
129. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., and Lynch, M. (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140. doi: 10.1158/1535-7163.MCT-08-0013
130. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109. doi: 10.1158/0008-5472.CAN-04-1443
131. Yamamoto, Y., De Velasco, M. A., Kura, Y., Nozawa, M., Hatanaka, Y., Oki, T., et al. (2015). Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. J. Transl. Med. 13, 150. doi: 10.1186/s12967-015-0509-x
132. Yang, F., Teves, S. S., Kemp, C. J., and Henikoff, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta 1845, 84-89. doi: 10.1016/j.bbcan.2013.12.002
133. Yang, Z., and Ming, X. F. (2012). mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases. Obes. Rev. 13(Suppl. 2), 58-68. doi: 10.1111/j.1467-789X.2012.01038.x
134. Yi, P., Higa, A., Taouji, S., Bexiga, M. G., Marza, E., Arma, D., et al. (2012). Sorafenib-mediated targeting of the AAA+ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol. Cancer Ther. 11, 2610-2620. doi: 10.1158/1535-7163.MCT-12-0516
135. Yin, J. Q., and Wan, Y. (2002). RNA-mediated gene regulation system: now and the future (Review). Int. J. Mol. Med. 10, 355-365. doi: 10.3892/ijmm.10.4.355
136. Yoneda, T., Imaizumi, K., Oono, K., Yui, D., Gomi, F., Katayama, T., et al. (2001). Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J. Biol. Chem. 276, 13935-13940. doi: 10.1074/jbc. M010677200
137. Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., et al. (2005). The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869. doi: 10.1038/sj.onc.1208841
138. Yuan, H., Li, A.-J., Ma, S.-L., Cui, L.-J., Wu, B., Yin, L., et al. (2014). Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J. Gastroenterol. 20, 4953-4962. doi: 10.3748/wjg.v20.i17.4953
139. Yuan, H. X., Russell, R. C., and Guan, K. L. (2013). Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy 9, 1983-1995. doi: 10.4161/auto.26058
140. Zhai, B., Hu, F., Jiang, X., Xu, J., Zhao, D., Liu, B., et al. (2014). Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol. Cancer Ther. 13, 1589-1598. doi: 10.1158/1535-7163.MCT-13-1043
141. Zhai, B., Jiang, X., He, C., Zhao, D., Ma, L., Xu, L., et al. (2015). Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 36, 2323-2334. doi: 10.1007/s13277-014-2839-3
142. Zhang, C. Z., Wang, X. D., Wang, H. W., Cai, Y., and Chao, L. Q. (2015). Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression. J. BUON 20, 218-222.
143. Zheng, B., Zhu, H., Gu, D., Pan, X., Qian, L., Xue, B., et al. (2015). MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem. Biophys. Res. Commun. 459, 234-239. doi: 10.1016/j.bbrc.2015.02.084
144. Zhou, F., Yang, Y., and Xing, D. (2011). Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 278, 403-413. doi: 10.1111/j.1742-4658.2010.07965.x